Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Three-Year Growth Hormone Treatment in Short Children with X-Linked Hypophosphatemic Rickets: Effects on Linear Growth and Body Disproportion

Three-Year Growth Hormone Treatment in Short Children with X-Linked Hypophosphatemic Rickets:... AbstractContext:Children with X-linked hypophosphatemic rickets (XLH) are prone to progressive disproportionate stunting despite oral phosphate and vitamin D treatment.Objective:Our objective was to analyze the effects of GH treatment on stature and lengths of linear body segments in short children with XLH.Design, Settings, and Patients:A 3-yr randomized controlled open-label GH study in short prepubertal children with XLH (n = 16) on phosphate and calcitriol treatment was conducted. A cohort of XLH patients (n = 76) on conservative treatment served as an XLH reference population.Main Outcome Measures:Changes in sd scores (SDS) of stature and linear body segments, i.e. sitting height, leg and arm length, and sitting height index (i.e. ratio between sitting height and stature) were the main outcome measures.Results:XLH patients presented at time of enrollment with significant impairments of stature (−3.3 SDS) and linear body segments compared with healthy children. Leg length (−3.8 SDS) was most impaired, whereas sitting height (−1.7 SDS) was best preserved. The markedly elevated mean sitting height index (+3.3 SDS) reflected severe body disproportion. GH resulted in a sustained increase in linear growth (stature, +1.1 SDS; sitting height, +1.3 SDS; leg length, +0.8 SDS; arm length, +1.1 SDS; each P < 0.05 vs. baseline), whereas no significant changes were observed in controls. Mean height SDS at 3 yr did not significantly differ between groups. Sitting height index remained stable in both the GH-treated patients and in study controls but increased further in the XLH-reference population.Conclusions:The 3-yr GH treatment improved linear growth without progression of body disproportion in short children with XLH. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Endocrinology and Metabolism Oxford University Press

Three-Year Growth Hormone Treatment in Short Children with X-Linked Hypophosphatemic Rickets: Effects on Linear Growth and Body Disproportion

Download PDF
9 pages

Loading next page...
 
/lp/oxford-university-press/three-year-growth-hormone-treatment-in-short-children-with-x-linked-feOMARTuLJ

References (56)

Publisher
Oxford University Press
Copyright
Copyright © 2011 by The Endocrine Society
ISSN
0021-972X
eISSN
1945-7197
DOI
10.1210/jc.2011-0399
pmid
21994957
Publisher site
See Article on Publisher Site

Abstract

AbstractContext:Children with X-linked hypophosphatemic rickets (XLH) are prone to progressive disproportionate stunting despite oral phosphate and vitamin D treatment.Objective:Our objective was to analyze the effects of GH treatment on stature and lengths of linear body segments in short children with XLH.Design, Settings, and Patients:A 3-yr randomized controlled open-label GH study in short prepubertal children with XLH (n = 16) on phosphate and calcitriol treatment was conducted. A cohort of XLH patients (n = 76) on conservative treatment served as an XLH reference population.Main Outcome Measures:Changes in sd scores (SDS) of stature and linear body segments, i.e. sitting height, leg and arm length, and sitting height index (i.e. ratio between sitting height and stature) were the main outcome measures.Results:XLH patients presented at time of enrollment with significant impairments of stature (−3.3 SDS) and linear body segments compared with healthy children. Leg length (−3.8 SDS) was most impaired, whereas sitting height (−1.7 SDS) was best preserved. The markedly elevated mean sitting height index (+3.3 SDS) reflected severe body disproportion. GH resulted in a sustained increase in linear growth (stature, +1.1 SDS; sitting height, +1.3 SDS; leg length, +0.8 SDS; arm length, +1.1 SDS; each P < 0.05 vs. baseline), whereas no significant changes were observed in controls. Mean height SDS at 3 yr did not significantly differ between groups. Sitting height index remained stable in both the GH-treated patients and in study controls but increased further in the XLH-reference population.Conclusions:The 3-yr GH treatment improved linear growth without progression of body disproportion in short children with XLH.

Journal

Journal of Clinical Endocrinology and Metabolism – Oxford University Press

Published: Dec 1, 2011

There are no references for this article.